International registry of spinal dural arteriovenous fistula outcomes
Official title: SPIDER - Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry
Run by Thomas Jefferson University · NCT07574645 · Data updated 2026-11-12
This registry will collect treatment and outcome data from people with spinal dural arteriovenous fistulas to see which treatments and factors relate to recovery.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | January 5, 2026 |
| Main results expected | May 2026 |
| Study ends | May 2026 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT07574645 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with imaging-confirmed type 1 spinal dural arteriovenous fistulas who have undergone surgical or endovascular treatment and have at least one recorded primary outcome.
✕Probably not a fit
Patients with other types of spinal vascular malformations, untreated SDAVFs, or no available outcome data are unlikely to be included or to directly benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Type 1 spinal dural arteriovenous fistulas (SDAVFs) are a rare but important cause of progressive myelopathy that are often underdiagnosed and variably treated. This international, multicenter registry pools de-identified patient-level data from contributing centers to create a large dataset of surgically or endovascularly treated SDAVF cases with at least one primary outcome recorded. Researchers will use standardized clinical scales and harmonized variables to analyze diagnostic delays, treatment strategies (endovascular, surgical, or combined), recurrence rates, and predictors of functional outcome. The registry is designed to provide more generalizable evidence than single-center series and to inform clinical decision-making and benchmarking across institutions.
Why it matters
Potential benefit: If successful, this registry could clarify which treatments and care pathways lead to better long-term function and faster diagnosis for people with SDAVF.
How similar studies have gone: Previous evidence has relied on single-center retrospective series, so while registries in other rare vascular conditions have been informative, a large international SDAVF registry of this scope is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 1 spinal dural arteriovenous fistula, confirmed on imaging * Surgically or endovascularly treated * At least 1 available primary outcome
Where it's running
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Pascal Jabbour, MD
- Email: pascal.jabbour@jefferson.edu
- Phone: 215-955-7000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multicenter Registry of Intracranial Dural Arteriovenous Fistulas in China
This study will collect and analyze data from many hospitals in China to see how common intracranial dural AV fistulas are, how they’re treated, and what outcomes look like for patients.
-
NAIF 2.0: See if glymphatic flow changes after dAVF treatment
This study tests whether the brain’s waste-clearance system changes after endovascular treatment for intracranial dural arteriovenous fistulas in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.